This Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of Tirzepatide once weekly in adults with obesity or overweight with at least one weight-related comorbidity, without diabetes. The primary objective was to demonstrate the superiority of Tirzepatide over placebo in mean percent change in body weight.

A randomized, double-blind, placebo-controlled, multicenter trial to determine the effect of a new diabetes drug on major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease. Participants will be followed for up to 5 years.

This is a Phase 1/2 open-label study to determine the safety and efficacy of a novel CAR-T cell therapy in patients with relapsed or refractory Non-Hodgkin Lymphoma. The Phase 1 portion will focus on dose-escalation, while Phase 2 will assess the overall response rate.

A Phase 3, randomized, observer-blind, placebo-controlled trial to assess the efficacy, safety, and immunogenicity of an RSV vaccine in older adults. The primary endpoint is the prevention of lower respiratory tract disease caused by RSV.

A 12-week, Phase 2, randomized, double-blind, vehicle-controlled study to evaluate the efficacy, safety, and tolerability of a new topical cream for the treatment of moderate to severe atopic dermatitis in adults and adolescents. Improvement in skin lesions and itch will be measured.